Effects of Ticlopidine of Platelet Function in Men with Stable Angina Pectoris

Summary

The effects of ticlopidine (T) (500 mg daily) on platelet function were investigated in a double-blind placebo-controlled study in 38 middle-aged men with stable incapacitating angina pectoris. The in vitro platelet reactivity to aggregating agents, the platelet sensitivity to prostacyclin and the plasma levels of platelet specific proteins and fibrinogen were determined before and after 4 and 8 weeks of treatment. T exerted a potent inhibitory effect on ADP- and collagen-induced platelet aggregation. The effect of T was proportional to the pretreatment reactivity to ADP and collagen. The inhibitory effect of T on the epinephrine response was less pronounced. The plasma levels of beta-thromboglobulin, platelet factor 4 and fibrinogen were not influenced by T. The platelet inhibition of prostacyclin was potentiated by T, and it was demonstrated that T and prostacyclin had synergistic inhibitory effects on platelet aggregation.

Key words

Ticlopidine - Platelet function - Angina pectoris - Prostacyclin

• References

• 1 Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 420-425
• 2 Mehta J, Mehta P. Role of blood platelets and prostaglandins in coronary artery disease. Am J Cardiol 1981; 48: 366-373
• 3 Salky N, Dugdale M. Platelet abnormalities in ischemic heart disease. Am J Cardiol 1973; 32: 612-617
• 4 Steele PP, Weily HS, Davies H, Genton E. Platelet function studies in coronary artery disease. Circulation 1973; 48: 1194-1200
• 5 Mustard JF, Kinlough-Rathbone RL, Packham MA. Prostaglandins and platelets. Annu Rev Med 1980; 31: 89-96
• 6 Lewis HD, Davis JW, Archibald DG, Stienke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396-403
• 7 Gitler B, Spielmane E. Efficacy of antiplatelet drugs in the maintenance of aortocoronary vein bypass graft patency. Am Heart J 1983; 106: 563-570
• 8 Kirstein P, Jogestrand T, Johnsson H, Olsson AG. Antiaggregatory physiological and clinical effects of Ticlopidine in subjects with peripheral atherosclerosis. Atherosclerosis 1980; 36: 471-480
• 9 Klingemann HG, Egbring R. Thrombozyten-Release-Proteine im Plasma bei arterieller VerschluBkrankheit unter Ticlopidine-Medika-tion. Dtsch Med Wochenschr 1982; 107: 1388-1391
• 10 Gensini GF, Favilla S, Breschi C, Abbate R, Costanzo G, Neri Semeri GG. Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. Haemostasis 1983; 13: 294-300
• 11 Violi F, Alessandri C, Frattaroli S, Ghiselli A, Balsano F. Effects of Ticlopidine on platelet function and blood coagulation. Thromb Haemostas 1982; 48: 166-168
• 1 Lecrubier C, Conard J, Samana M, Bousser MG. Essai randomise d‘un nouvel agent anti-agregant: la Ticlopidine. Therapie 1977; 32: 189-194
• 13 Knudsen JB, Gormsen J. The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro. Thromb Res 1979; 16: 663-671
• 14 Conard J, Lecrubier C, Scarabin PY, Horellou MH, Samana M, Bousser MG. Effects of long-term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980; 20: 143-148
• 15 Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol 1982; 35: 740-743
• 16 Born G VR, Cross MJ. The aggregation of blood platelets. J Physiol 1965; 168: 178-195
• 17 Gormsen J, Dalsgaard Nielsen J, Agerskov Andersen L. ADP-induced platelet aggregation in vitro in patients with ischemic heart disease and peripheral thromboatherosclerosis. Acta Med Scand 1977; 201: 509-513
• 18 Sinzinger H, Kaliman J, Widhalm K, Pachinger O, Probst P. Value of platelet sensitivity to antiaggregatory prostaglandins (PGI2, PGE1, PGD2) in 50 patients with myocardial infarction at young age. Prostaglandins Med 1981; 7: 125-32
• 19 Ludlam CA, Cash JD. Studies on the liberation of beta-thrombo-globulin from human platelets in vitro. Br J Haematol 1976; 33: 239-247
• 20 Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
• 21 Desvignes P, Bonnet P. Direct determination of plasma fibrinogen levels by heat precipitation. A comparision of the technique thrombin clottable fibrinogen with spectophotometry and radial immunodiffusion. Clin Chim Acta 1981; 110: 9-17
• 22 Thébault JJ, Blatrix CE, Blanchard JF, Panak EA. Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 1975; 18: 485-490
• 23 David JL, Monfort F, Herion F, Raskinet R. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb Res 1979; 14: 35-49
• 24 Pumphrey CW, Dawes J. Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disesase and after myocardial infarction. Am J Cardiol 1982; 50: 1258-1261
• 25 Ashida S-I, Abiko Y. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. Thromb Haemostas 1979; 41: 436-449
• 26 Bonne C, Martin B, Regnault F. Hypothetic mechanism of ticlopidine-induced hypersensitivity to PGE1 in rat platelets. Thromb Res 1981; 21: 157-164
• 27 Toung CC, Ferand C, Aubert D, Loubrie J-C, Tuong A. Modulation of the inhibitory action of prostaglandin El on platelet aggregation in rats: a study with ticlopidine aspirin, dipyridamole and sulphin-pyrazone. Biochem Pharmacol 1982; 31: 1147-1150
• 28 Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979; 300: 1142-1147
• 29 Bruno JJ. The mechanism of action of ticlopidine. Thromb Res 1983; (Suppl. 04) 59-67
• 30 Lee H, Paton RC, Ruan C, Caen JP. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets. Thromb Haemostas 1981; 46: 590-592
• 31 Lips J PM, Sixma JJ, Schiphorst ME. The effect of ticlopidine administration to humans on the binding of adenosine diphosphate to blood platelets. Thromb Res 1980; 17: 19-27
• 32 Stoltz JF, Solagna S, Nicolas A, Verry M. Study of membrane physico-chemical mechanism of the platelet anti-aggregating effect of ticlopidine. Thromb Haemostas 1981; 46: 412 (Abstr)
• 33 Daveloose D, Sablayrolles M, Molle D, Leterrier F. Interaction of ticlopidine with the erythrocyte membranee. Biochem Pharmacol 1982; 31: 3949-3954
• 34 Dunn FW, Soria J, Soria C, Thomaides A, Lee H, Caen JB. In vivo effect of Ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets. Agents Actions suppl 1984; 15: 97-104
• 35 Neri Serneri GG, Masotti G, Poggesi L, Galanti G, Morettini A, Scarti L. Reduced prostacyclin production in patients with different manifestations of ischemic heart disease. Am J Cardiol 1982; 49: 1146-1150
• 36 Lecrubier C, Girard P, Noire P, Samana M. Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients. Agents Actions suppl 1984; 15: 60-67
• 37 Random J, Lefort J, Vargaftig B. Comparison between the anti-aggregating effect of Ticlopidine in whole blood, PRP and washed platelets in the rat. Thromb Res 1982; 26: 13-20
• 38 Haslam RJ, McClenaghan MD. Measurement of circulating prostacyclin. Nature 1981; 292: 364-366